autologous activated lymphocytes + interleukin-2 + interferon-alpha

This combination immunotherapy strategy involves the administration of autologous activated lymphocytes (AAL) in conjunction with systemic cytokines, interleukin-2 (IL-2) and interferon-alpha (IFN-alpha). Developed by Assistance Publique - Hôpitaux de Paris, the treatment was specifically evaluated for metastatic renal cell carcinoma (mRCC), a malignancy known for its resistance to standard chemotherapy. The therapeutic rationale relies on the direct anti-tumor cytotoxicity of the patient's own lymphocytes, which are harvested, activated, and expanded *ex vivo* before re-infusion. The concurrent systemic administration of IL-2 and IFN-alpha is intended to provide broad, non-specific immune stimulation, promoting the proliferation, survival, and anti-tumor activity of both the infused AALs and endogenous immune cells such as T-cells and natural killer (NK) cells. A Phase I/II clinical trial investigating this combination was sponsored by Assistance Publique - Hôpitaux de Paris but was ultimately terminated.

Other names

AAL + IL-2 + IFN-alphaautologous activated lymphocytes plus interleukin-2 and interferon-alpha